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ABSTRACT
Background    Diuretics are essential for treating acute 
decompensated heart failure (ADHF), but the response 
is inconsistent. This study aimed to clarify whether 
kidney volume as assessed by ultrasound (US) predicts 
diuretic resistance in patients with ADHF. 
Methods    We enrolled 29 patients with ADHF and 32 
controls. Height-adjusted kidney volume was assessed 
by US. We divided patients into two groups based on 
the median value of total daily use of furosemide (intra-
venous dose plus 0.5 × oral dose of furosemide equiva-
lents) during 3 days from admission. 
Results    Patients with ADHF had a significantly small-
er left kidney volume than did control subjects (27.7 ± 
10.0 vs. 32.8 ± 8.8 mL/m, P < 0.05). Patients in the high-
dose furosemide group (≥ 51.7 mg/d) had a significantly 
lower estimated glomerular filtration rate (eGFR) and a 
significantly smaller kidney volume than did those in the 
low-dose furosemide group (eGFR: 43.9 ± 20.4 vs. 60.8 
± 21.6 mL/min/1.73 m2, left kidney volume: 23.2 ± 5.2 
vs. 32.6 ± 11.0 mL/m, right kidney volume: 26.5 ± 7.5 
vs. 32.6 ± 7.9 mL/m, all P < 0.05). Multivariate logistic 
analysis showed that left kidney volume, but not eGFR, 
was independently associated with the requirement of 
high-dose furosemide (odds ratio: 0.856, 95% confidence 
interval: 0.735–0.997, P < 0.05).
Conclusion    Kidney volume as assessed by US is a 
useful predictor of diuretic resistance in patients with 
ADHF.
Key words    acute decompensated heart failure; diuretic 
resistance; kidney volume; ultrasound examination
A lack of adequate relief of symptoms is associated with 
a longer hospital stay and increased mortality. Therefore, 
early and effective decongestion for improving outcomes 
in acute decompensated heart failure (ADHF) is import-
ant.1, 2 Intravenous furosemide is currently prescribed for 
approximately 90% of hospitalized patients with ADHF 
to relieve congestion.3 However, there is an ADHF 
subpopulation with diuretic resistance who are at high 
risk for morbidity and mortality.4 Previous studies have 
shown that renal impairment is one of the determinants 
of a poor diuretic response in patients with ADHF.5–8 
In a stable hemodynamic state, serum creatinine levels, 
estimated glomerular filtration rate (eGFR), and blood 
urea nitrogen (BUN) levels are good parameters for re-
nal function.9 However, in ADHF, several factors affect 
the value of these renal biomarkers7, 10, 11 and a conven-
tional renal function test may be insufficient to identify 
patients at high risk for diuretic resistance.12, 13
 Kidney volume is decreased with glomerular scle-
rosis and tubular atrophy. Kidney volume is a simple 
estimate of renal reserve and function in patients with 
suspected renal diseases.14 However, the relationship 
between kidney size and diuretic resistance in ADHF 
remains unknown. The present study aimed to clarify 
whether kidney volume as assessed by ultrasound (US) 
predicts diuretic resistance in patients with ADHF.  
SUBJECTS AND METHODS
Subjects
The present study enrolled 29 consecutive patients 
with ADHF who were hospitalized in Tottori Univer-
sity Hospital from April 2014 to November 2015. They 
agreed to participate in this study within 48 hours after 
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hospitalization. ADHF was defined as new-onset de-
compensated heart failure or decompensation of chronic 
heart failure as previously described.15 Acute coronary 
syndrome was excluded. Heart failure (HF) was defined 
according to Framingham criteria, together with pulmo-
nary congestion on X-rays or pulmonary hypertension 
as evaluated by Doppler echocardiography. The control 
group consisted of 32 age- and sex-matched patients 
without a previous history of HF who were hospitalized 
for inspection of the gastrointestinal tract or the liver. 
Patients with malignancy, a unilateral kidney, polycystic 
kidney disease, and those who received regular hemodi-
alysis were excluded. 
Data collection
Medical records were reviewed for demographics, lab-
oratory data, echocardiograms, medications, and thera-
peutic response. All measurements were obtained on ad-
mission. Kidney volume was assessed by an abdominal 
US examination within 48 hours after hospitalization. 
The estimated glomerular filtration rate (eGFR) was 
determined by the modified Modification of Diet and 
Renal Disease study formula for Japanese: eGFR=194 × 
(age−0.287) × (serum creatinine−1.094) × (0.739 if female).16 
We defined the severity of chronic kidney disease (CKD) 
based on the guideline of CKD9 as follows: normal, 
eGFR ≥ 90 mL/min/1.73 m2; mild, eGFR ≥ 60 and < 
90 mL/min/1.73 m2; moderate, eGFR ≥ 30 and < 60 
mL/min/1.73 m2; and severe, eGFR < 30 mL/min/1.73 
m2. We evaluated the therapeutic response in the acute 
phase, including total urine volume, change in body 
weight, and improvement of New York Heart Associa-
tion class and signs of congestion, during the first 3 days 
from admission. All of the patients received intravenous 
(i.v.) furosemide for 3 days. At our hospital, the initial i.v. 
dose of furosemide was 40 mg/d according to the Eu-
ropean Society of Cardiology (ESC) guidelines.17 After 
judgement of response to furosemide every a few hours, 
the attending physician changed the i.v. dose of furose-
mide to maintain water balance appropriately.
 The same quantity of oral diuretics before hospital-
ization was continued during this period. The dose of oral 
loop diuretics was converted to furosemide equivalents as 
follows: 60 mg of azosemide = 40 mg of furosemide.18, 19 
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Fig. 1. Representative ultrasonic images and computed tomography images for measurement of kidney size. A: Representative ultrasonic 
images. B: Representative computed tomography images, a: axial image, b: coronal image, c: sagittal image, and d: three-dimensional 
reconstructive image. D, depth; L, maximum length; W, width. 
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Total daily use of furosemide was defined as the i.v. dose 
of furosemide plus 0.5 × oral dose of furosemide equiva-
lents for 3 days, taking into account biological availability 
as previously described.20 We defined a high dose of fu-
rosemide as ≥ 51.7 mg/d or based on the median value of 
total daily use of furosemide. The patients were divided 
into two groups: low-dose group (< 51.7 mg/d, n = 16) and 
high-dose group (≥ 51.7 mg/d, n = 13). 
Renal US examination 
All renal US examinations were performed using stan-
dard grayscale B-mode imaging on an Aplio 500 Ul-
trasound System (Toshiba Medical Systems, Tochigi, 
Japan) with a 3.5-MHz convex transducer. One experi-
enced US physician measured all US parameters. Renal 
length measurements were performed with patients 
in the supine position using US. The maximum renal 
length (L) and width (W) were obtained from longitu-
dinal images in planes ranging from sagittal to coronal. 
The depth (D) was obtained from transverse images of 
the mid-kidney acquired in the plane perpendicular to 
the longitudinal plane (Fig 1A). 
 Kidney volume was determined using the formula 
for an ellipsoid (π/6 × L × W × D),21 and was adjusted 
for the individual’s height as previously described.22 
Kidney volume as assessed by computed to-
mography
The accuracy of kidney volume as calculated with US 
was evaluated by comparing it with that assessed by 
computed tomography (CT). Eleven patients with ADHF 
underwent thoracic and abdominal CT to identify the 
cause of infection and pleural effusion on admission to 
hospital. In this study, we used a 3D-imaging analysis 
system (SYNAPSE VINCENT; Fuji Photo Film, Tokyo, 
Japan) to calculate bilateral kidney volume (Fig. 1B). 
This system is available for automatic extraction of or-
gan and automatic volume measurement, and its applica-
tion with organs of the whole body has been reported.23
 This study conformed with the principles outlined 
in the Declaration of Helsinki and was approved by the 
institutional review board for human investigation at 
Tottori University Hospital (approval number: 2467). 
Written informed consent was provided by each subject. 
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation for normally distributed variables, and medi-
an and interquartile range for non-normally distributed 
variables. The normality of distribution was assessed by 
the Kolmogorov–Smirnov test. Differences in continu-
ous variables between the two groups were compared 
using the t-test for normally distributed variables and the 
Mann–Whitney U test for non-normally distributed vari-
ables. Categorical variables are expressed as percentag-
es. Categorical variables were compared using Fisher’s 
exact test. Correlations of continuous variables between 
the two groups were tested by Spearman’s rank correla-
tion coefficient and Bland–Altman plots. Multivariate 
logistic regression models were performed to assess the 
independent predictors of the requirement for high-dose 
furosemide. All baseline variables with P < 0.05 in uni-
variate analysis were entered into the analysis. A P value 
< 0.05 was considered significant. All analyses were 
performed using EZR (Saitama Medical Center, Jichi 
Medical University), which is a graphical user interface 
for R (The R Foundation for Statistical Computing, ver-
sion 2.13.0), and XLSTAT for Microsoft Excel (Micro-
soft, Redmond, WA). 
RESULTS
Patients’ characteristics between the control and 
ADHF groups
The patients’ characteristics in the ADHF group are 
shown in Tables 1 and 2. The mean age was 75 ± 14 
years and 51.7% were men. The etiology of HF was isch-
emic heart disease in 24.1%, valvular heart disease in 
20.7%, and cardiomyopathy in 24.1% of patients. Mean 
left ventricular ejection fraction was 44.2 ± 18.5%, and 
HF with preserved ejection fraction (> 45%) was preva-
lent in 44.8% of patients. More than half of the patients 
had New York Heart Association class IV and “warm 
and wet” as assessed by noninvasive classification of 
ADHF.24 
 The patients’ characteristics in the control group are 
shown in Table 1. The ADHF group had significantly 
higher levels of BUN and creatinine, and a lower eGFR 
compared with the control group (all P < 0.05). There 
were no significant differences in other well-known 
factors related to kidney size, including age, sex, height, 
and body weight, as well as the prevalence of hyperten-
sion and diabetes,25 between the two groups. 
Kidney volume between the control and ADHF 
groups
Figure 2 shows the correlation of kidney volume as as-
sessed by US with that as assessed by CT. We found a 
good linear correlation between the two measurements 
in Spearman’s rank correlation coefficient analysis (left: 
r = 0.979, P < 0.001; right: r = 0.973, P < 0.001, Fig. 2A). 
Bland–Altman plots showed that the mean difference in 
kidney volume between CT and US was 5.66 mL (left) 
and 2.62 mL (right), and the standard deviation was 
138
S. Sugihara et al.
Table 1. Patients’ characteristics in the control and ADHF groups
control group ADHF group P-value
(n = 32) (n = 29)
Demographics
Age (years) 70 ± 14 75 ± 14 0.158
Male (%) 65.6 51.7 0.278
Height (cm) 160.4 ± 9.4 159.6 ± 8.7 0.729
Body weight (kg) 60.7 ± 11.8 59.3 ± 15.5 0.685
Systolic blood pressure (mmHg) 130 ± 21 124 ± 25 0.509
Heart rate (beats/min) 73 ± 10 85 ± 20 0.057
Comorbidity conditions
Hypertension (%) 56.5 62.1 0.651
Diabetes (%) 28.1 34.5 0.600
Dyslipidemia (%) 50.0 31.0 0.350
Chronic obstructive disease (%) 22.6 20.7 0.862
Laboratory values
BUN (mmol/L) 5.2 ± 1.8 9.2 ± 6.2 0.003
Creatinine (umol/L) 72.4 ± 22.0 99.9 ± 57.5 0.015
eGFR (mL /min/1.73 m2) 71.0 ± 24.1 53.2 ± 22.4 0.004
Severity of CKD: 0.005
Normal/mild/moderate/severe (%) 18.8/43.8/37.4/0.0 6.9/27.6/55.2/10.3
Data are mean ± SD or percentage. Severity of CKD was classifi ed as follows: normal, eGFR ≥ 90 mL/min/1.73 m2; mild, eGFR ≥ 60 and 
< 90 mL/min/1.73 m2; moderate, eGFR ≥ 30 and < 60 mL/min/1.73 m2; and severe, eGFR < 30 mL/min/1.73 m2. 
ADHF, acute decompensated heart failure; BUN, blood urea nitrogen; CKD, chronic kidney disease; eGFR, estimated glomerular rate. 
Fig. 2. Correlation of kidney volume calculated by US and CT. A: Spearman’s rank correlation coeffi cient analysis of the left and right 
kidneys. B: Bland–Altman plots of the left and right kidneys. The mean differences in the volume of CT and US were 5.66 mL (left) and 2.62 
mL (right), and the SD was 13.45 mL (left) and 14.28 mL (right). CT, computed tomography; US, ultrasound. 
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13.45 mL (left) and 14.28 mL (right, Fig. 2B). 
 Figure 3 shows the height-adjusted kidney volume 
of the control and ADHF groups. Left kidney volume in 
the ADHF group was significantly lower than that in the 
control group (27.7 ± 10.0 mL/m vs. 32.8 ± 8.8 mL/m, P 
< 0.05). Right kidney volume and the mean left and right 
kidney volumes in the ADHF group were also slightly 
smaller than those in the control group, but they did not 
reach significance (29.4 ± 8.2 mL/m vs. 31.5 ± 11.0 mL/
m, P = 0.412, 28.6 ± 8.1 mL/m vs. 32.1 ± 9.0 mL/m, P = 
0.110, respectively). 
Table 2. Baseline characteristics of patients with ADHF in the low-dose and high-dose furosemide groups
Low dose group High dose group P-value
(n = 16) (n = 13)
Demographics
Age (years) 74 ± 13 76 ± 16 0.771
Male (%) 62.5 38.5 0.211
Prior heart failure hospitalization (%) 43.7 46.2 0.902
Height (cm) 161.4 ± 7.9 157.5 ± 9.5 0.240
Body weight (kg) 61.4 ± 18.4 56.7 ± 11.1 0.413
Systolic blood pressure (mmHg) 120 ± 23 129 ± 28 0.322
Heart rate (beats/min) 85 ± 16 87 ± 25 0.785
NYHA class III/IV (%) 75.0/25.0 61.5/38.5 0.454
Noninvasive classification of ADHF: 
Warm/cold, wet/dry 75.0/25.0, 100.0/0.0 84.6/15.4, 84.6/15.4 0.542/0.111
Clinical scenario: 1/2/3/5 25.0/43.8/12.5/18.7 23.1/69.2/7.7/0.0 0.686
LVEF (%) 46.0 ± 20.6 44.1 ± 16.0 0.782
Comorbidities
Coronary artery disease (%) 18.8 30.8 0.470
Hypertension (%) 62.5 61.5 0.959
Diabetes (%) 23.1 33.3 0.587
Laboratory values
Sodium (mmol/L) 138.8 ± 4.6 142.0 ± 5.9 0.113
Albumin (g/L) 32.7 ± 7.5 35.2 ± 6.7 0.390
BNP (pg/mL) 1256 (480–1437) 1015 (318–1218) 0.548
BUN (mmol/L) 7.5 ± 2.6 11.3 ± 8.7 0.100
Creatinine (umol/L) 82.2 ± 26.5 121.1 ± 76.6 0.068
eGFR (mL/min/1.73 m2) 60.8 ± 21.6 43.9 ± 20.4 0.040
Severity of CKD:
Normal/mild/moderate/severe (%) 12.5/31.3/56.2/0.0 0.0/15.4/61.5/23.1 0.018
Pre-hospital medication
ACEI/ARB (%) 50.0 58.3 0.685
β-blocker (%) 38.5 50.0 0.580
MRA (%) 12.5 15.4 0.830
Loop diuretics (%) 31.3 76.9 0.013
Thiazide (%) 12.5 7.7 0.686
Tolvaptan (%) 0.0 0.0 1.000
Data are mean ± SD or median (interquartile range). Severity of CKD was classified as follows: normal, eGFR ≥ 90 mL/min/1.73 m2; 
mild, eGFR ≥ 60 and < 90 mL/min/1.73 m2; moderate, eGFR ≥ 30 and < 60 mL/min/1.73 m2; and severe, eGFR < 30 mL/min/1.73 m2. 
ACEI, angiotensin-converting enzyme inhibitor; ADHF, acute decompensated heart failure; ARB, angiotensin receptor blocker; BNP, 
B-type natriuretic peptide; BUN, blood urea nitrogen; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LVEF, 
left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association. 
Characteristics of patients with ADHF in the low-
dose and high-dose furosemide groups
Table 2 shows baseline characteristics of patients with 
ADHF between the low-dose and high-dose groups. 
Patients in the high-dose group had a significantly lower 
level of eGFR than did those in the low-dose group (P < 
0.05). Serum levels of BUN and creatinine also tended 
to be higher in the high-dose group than in the low-dose 
group. The prescription rate of oral loop diuretics before 
hospital admission was significantly higher in the high-
dose group than in the low-dose group (P < 0.05). There 
were no significant differences in age, sex, height, body 
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weight, medical history, and other laboratory data be-
tween the two groups. 
In-hospital treatment and therapeutic response in 
ADHF in the low-dose and high-dose furosemide 
groups
Table 3 shows the in-hospital treatment and therapeutic 
responses during 3 days after admission to hospital. All 
of the patients received i.v. furosemide for 3 days, and 
the daily mean i.v. dose was 37.4 ± 18.4 mg/d (20–100.0 
mg/d). The dose of oral diuretics prescribed before hos-
pitalization was not changed during this period, and the 
daily oral dose was 43.3 ± 23.8 mg/d (20.0–120.0 mg/d). 
Patients in the high-dose group more frequently received 
a higher daily dose of i.v. furosemide (47.4 ± 18.1 vs. 
26.3 ± 11.9 mg/d, P < 0.05), as well as a higher daily 
dose of oral furosemide (56.9 ± 24.3 vs. 32.2 ± 17.2 
mg/d, P < 0.05), compared with those in the low-dose 
group. Additionally, patients in the high-dose group had 
a higher prescription rate and dosage of carperitide than 
did those in the low-dose group (92.3% vs. 56.3%, 0.021 
± 0.01 vs. 0.010 ± 0.001 γ, all P < 0.05). There were no 
significant differences in therapeutic responses, includ-
ing a change in body weight, total urine volume, and 
improvement of symptoms and congestion between the 
two groups. Therefore, patients in the high-dose group 
required more intensive decongestion therapy for the 
same degree of improvement compared with the low-
dose group. 
Kidney volume in ADHF in the low-dose and high-
dose furosemide groups
Figure 4 shows kidney volume in ADHF between the 
low-dose and high-dose groups. Left and right kidney 
volumes in the high-dose group were significantly small-
er than those in the low-dose group (left: 23.2 ± 5.2 vs. 
32.6 ± 11.0 mL/m, right: 26.5 ± 7.5 vs. 32.6 ± 7.9 mL/m, 
mean of both sides: 24.9 ± 3.9 vs. 32.6 ± 8.9 mL/m, all P 
< 0.05).  
 Table 4 shows multivariate logistic regression anal-
ysis for predicting the requirement of high-dose furo-
semide. In univariate analysis, eGFR and each kidney 
volume were significantly associated with high-dose 
furosemide. In multivariate analysis, left kidney volume, 
but not eGFR, remained an independent predictor of the 
requirement of high-dose furosemide (odds ratio: 0.856, 
95% confidence interval: 0.735–0.997, P < 0.05) (Table 
4).
DISCUSSION
This study showed that kidney volume as assessed by 
US independently predicted the required dose of furose-
mide at the acute phase of treatment of ADHF.
 Renal function is one of the determinants of a di-
uretic response in ADHF.4–8 However, in ADHF, several 
factors affect the value of renal function tests. Creatinine 
levels and eGFR are affected by fluid retention or a de-
crease in blood pressure.10 The level of BUN, a marker 
of reduced glomerular filtration,26 is also affected by co-
morbidities, such as liver disease and malnutrition.27 The 
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Fig. 3. Height-adjusted kidney volume in the control and ADHF groups. Patients in the ADHF group had a significantly smaller left kid-
ney volume than those in the control group. ADHF, acute decompensated heart failure.
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Table 3. In-hospital management, and therapeutic response of ADHF in the low-dose and high-dose furosemide 
groups
Low dose group High dose group P-value
 (n = 16)  (n = 13)
Furosemide 
Daily i.v. dose (mg/day) 26.3 ± 11.9 47.4 ± 18.1 0.001
Daily oral dose (mg/day) 32.2 ± 17.2 56.9 ± 24.3 0.003
Daily total dose (i.v. dose conversion) (mg/day) 42.5 ± 8.6 75.9 ± 18.7 < 0.001
Intravenous drugs
Carperitide (%) 56.3 92.3 0.031
Mean dose of carperitide (γ) 0.010 ± 0.001 0.021 ± 0.010 0.030
Nitroglycerin (%) 12.5 15.4 0.830
Inotropes (%) 12.5 23.1 0.471
Non-pharmacological management 
NPPV (%) 25.0 38.5 0.454
Intubation (%) 0.0 0.0 1.000
IABP/PCPS (%) 0.0 0.0 1.000
Ultrafiltration (%) 0.0 0.0 1.000
Therapeutic response 
Daily change in body weight, (kg/day) −0.7 ± 0.5 −0.8 ± 0.5 0.727
Daily urine volume, (mL/day) 2066 ± 683 2012 ± 724 0.841
Improvement of: 
NYHA class (%) 87.5 69.2 0.242
Peripheral edema (%) 50.0 30.8 0.374
Rales (%) 43.8 46.2 0.902
JVD (%) 18.8 15.4 0.820
Data are mean ± SD or percentage. 
ADHF, acute decompensated heart failure; IABP, intra-aortic balloon pumping; i.v., intravenous; JVD, jugular vein dilatation; NPPV, 
noninvasive positive pressure ventilation; NYHA, New York Heart Association; PCPS, percutaneous cardiopulmonary support. 
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Fig. 4. Height-adjusted kidney volume of ADHF in the low-dose and high-dose furosemide groups. Patients in the high-dose group had a 
significantly smaller kidney volume (left, right) than those in the low-dose group. ADHF, acute decompensated heart failure.
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Table 4. Multivariable logistic regression analyses for predicting the requirement of high-dose furosemide
OR 95% CI P-value
Average of left and right kidney volume 0.831 0.688–1.004 0.055
eGFR 0.973 0.927–1.021 0.263
Left kidney volume 0.856 0.735–0.997 0.045
eGFR 0.969 0.925–1.016 0.195
Right kidney volume 0.921 0.821–1.034 0.163
eGFR 0.966 0.921–1.012 0.149
CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio.
present study showed that, among renal biomarkers, only 
eGFR was significantly associated with a requirement 
for a high dose of furosemide. However, by multivariate 
analysis, eGFR no longer independently predicted di-
uretic resistance. This finding suggested insufficiency of 
these conventional markers in identifying patients at a 
high risk for diuretic resistance.
 Kidney volume is a simple estimate of renal reserve 
and function.13 Some studies have shown that kidney 
volume provides useful information on the risk and com-
plications in CKD beyond eGFR and albuminuria.13, 28 A 
previous study on ADHF reported that a shorter longi-
tudinal kidney length as assessed by CT was associated 
with a poor diuretic response.29 In this study, we showed 
the reliability of US in the measurement of kidney vol-
ume compared with CT. US has the advantage of no 
radiation exposure and can be conducted at the bedside. 
Therefore, the current study expanded previous findings 
by demonstrating that kidney volume as assessed by US 
is a convenient and noninvasive alternative to that as 
assessed by CT for identifying patients at high risk for 
diuretic resistance. 
 Interestingly we found that, in patients with ADHF, 
left kidney atrophy was predominantly observed, and 
was independently associated with diuretic resistance. 
Although this study had a small sample size, and cannot 
provide conclusive evidence, we speculate several possi-
ble mechanisms regarding the relation between the later-
ality of kidney size and the diuretic response. Davran et 
al. previously reported that there was a higher prevalence 
of left kidney atrophy than right kidney atrophy. Of 2417 
patients, 1.3% of patients had renal atrophy in the left 
side compared with 0.2% of patients with renal atrophy 
in the right side.30 The cause of left kidney atrophy is un-
clear, but a potential explanation is anatomical differenc-
es in the kidney. The left renal artery is shorter than the 
right renal artery because of the location of the aorta.31 
Davran et al. speculated that the left kidney is likely to 
receive a relatively high arterial pressure because of the 
shorter distance to the heart.30 This results in endothelial 
dysfunction and atherosclerosis, which cause poor per-
fusion of the left kidney.31, 32 Additionally, the left kidney 
is in contact with many organs, including the aorta, 
pancreas, spleen, stomach, small intestine, and colon. 
However, the right kidney contacts only three organs of 
the liver, right colon flexure, and duodenum.31 In ADHF, 
venous congestion elevates intra-abdominal pressure 
(IAP).33 The left kidney is more likely to be compressed 
by elevated IAP than the right kidney because many 
organs around the left kidney may form a close space 
and increase local IAP. Additionally, the left renal vein 
is approximately two or three times longer than the right 
renal vein, and is in contact with the aorta.31 Elevated 
IAP may also lead to left renal vein compression and 
congestion,34 contributing to poor left kidney perfusion 
and worsened renal function. The dominancy of left 
kidney atrophy remains a matter of speculation. Further 
investigations are necessary to evaluate the relationship 
between the laterality of kidney size and renal function. 
 This study has several limitations. First, there is a 
large difference in the dose of furosemide used between 
our study and previous studies conducted in Western 
countries. A dose trial showed that the daily dose of i.v. 
furosemide at the acute phase of treatment was approx-
imately 120 mg/d in the low-dose group and 260 mg/
d in the high-dose group.35 However, patients with HF 
in Japan require a lower dose of furosemide than those 
in Western countries. A phase III, randomized, dou-
ble-blind, placebo-controlled study (QUEST study) as-
sessed the efficiency and safety of tolvaptan in Japanese 
patients with ADHF.36 This previous study showed that 
volume overload, despite the use of an average daily dose 
of furosemide ≥ 40 mg, is defined as diuretic resistance. 
In our study, patients in the high-dose group received a 
high dose of furosemide of ≥ 40 mg/d (daily oral dose of 
56.9 ± 24.3 mg/d plus a daily i.v. dose of 47.4 ± 18.1 mg/
d), which indicated that they were accompanied by di-
uretic resistance. Second, this study had a small sample 
size and low statistical power. Furthermore, the effect of 
kidney volume on clinical outcomes was unclear. Fur-
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ther well-designed, large, prospective trials are required 
to clarify these issues. In conclusions, Kidney volume 
as assessed by US is helpful in identifying patients with 
ADHF at a high risk for diuretic resistance. 
The authors declare no conflict of interest. 
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